Phase II clinical development

Advancing Process and Data Toward Commercial Readiness

We help you strengthen your manufacturing and analytical foundations, building the process understanding, data integrity, and technical control needed to move to late-stage development and commercial readiness.

Phase II Clinical Development
Quick filter:

Early development proves a concept but once you move to Phases I and II you need to show it can deliver. As your program matures, so must your process, analytics, and documentation.

We help you transition your program to reliability — transforming early-stage chemistry into robust, well-understood processes ready for validation and scale.

Whether you’re refining synthetic routes, enhancing control strategies, or optimising solid forms and formulations, we provide the expertise to meet both project goals and regulatory expectations, giving you confidence in every batch and every data point.

How We Support You
Refining and Strengthening Processes
Enhance efficiency, reproducibility, and sustainability through optimisation, DoE, and advanced modelling.
Increase Process Understanding
Build deep process knowledge, including critical parameters, design space, and control strategies.
Validate Analytical Methods
Transition analytical methods from qualification to validation, ensuring traceability and compliance.
Optimise Solid-State and Formulation Properties
Refine crystallisation, polymorph control, and developability for consistent performance and manufacturability.
Prepare for Technology Transfer
Deliver complete technical packages, risk assessments, and process documentation ready for GMP or commercial scale.

Our Core, Phase II Capabilities

Process Design & Optimisation

• Model-led optimisation and process definition
• Design of experiments (DoE) and statistical analysis
• Green chemistry integration for yield and efficiency
• Demonstration batches to prove reproducibility and control

Analytical Excellence

• Method development, optimisation, and qualification aligned with ICH Q14
• Impurity profiling, forced degradation, and trace-level analysis
• Stability studies and shelf-life justification
• Analytical tech transfer to GMP sites

Crystallisation, Solid State & Pre-formulation

• Crystallisation development and control strategy definition
• Polymorph and salt screening
• Filtration, washing, and drying optimisation
• QbD-driven process robustness and control

Technology Transfer & Scale-Up

• Tech transfer packages and process knowledge documentation
• Risk assessment and deviation mitigation strategies
• Late-stage scale-up and sustainability evaluation
• Collaboration with CDMOs and CMOs for successful validation and handover

Led by Our Teams
Our Therapeutic Modalities
Therapeutic Modalities
Small Molecules
Our small molecule scientists design and optimise scalable, efficient routes that balance innovation with manufacturability. Our expertise spans route scouting, process chemistry, solid-state science, and HPAPI development, delivering chemistry that performs from lab to launch.
Explore more
Therapeutic Modalities
Oligonucleotides
Our oligonucleotide experts unite chemistry and analytics to accelerate RNA-based therapeutics. From sequence design to conjugation, they deliver decision-ready data and scalable solutions for siRNA, ASO, and emerging nucleic acid platforms.
Explore more
Therapeutic Modalities
Peptides
Specialists in complex peptide synthesis, modification, and purification, our team create high-quality linear, cyclic, and stapled peptides. They combine deep chemical insight with analytical rigour to deliver stability, purity, and performance in every sequence.
Explore more
Therapeutic Modalities
TACs and Glues
Our targeted protein degradation scientists bring together expertise in bifunctional design, linker chemistry, and biological testing. They turn complexity into robust process understanding - engineering degraders and molecular glues that are stable, scalable, and ready for development.
Explore more
Therapeutic Modalities
Hybrid Modalities
At the intersection of chemistry and biology, our hybrid modality scientists develop conjugates and multifunctional platforms that expand the therapeutic potential of these molecules. Our integrated approach ensures structural control, stability, and delivery across modalities.
Explore more
Therapeutic Modalities
Complex Synthetic Medicines
Our scientists excel at bridging modalities, integrating small molecule, peptide, and oligonucleotide expertise to develop hybrid constructs and next-generation therapeutics. They thrive on solving the challenges that sit at the edges of chemistry and biology.
Explore more

What This Stage Enables for Your Programme

We help you move through Phase II with confidence in your process, your data, and your readiness for the next stage.

Our work ensures the science behind your molecule can support the next level of scale, compliance, and consistency to transition seamlessly to Phase III or commercial scale.

Why It’s Different Working With Us

End-to-End Perspective
Every optimisation is made with commercial readiness in mind.
Safety and Sustainability First
Process safety and green chemistry embedded at every step.
Agile Development
Rapid route design and scalable execution that stand up to scrutiny.
Built for Collaboration
We integrate seamlessly with your CDMO, CMO, or internal teams.
1 / 1
“At Phase II, reliability becomes everything. We make sure every process, method, and dataset stands up to the scrutiny that defines the path to commercial success.”
Rob Crook
Director of Chemical Sciences

Book a Consultation

Speak directly with our scientists about your development challenges and see how we can support your program.